safety profile
Corvus’ Experimental Drug Delivers Strong Results in Hard-to-Treat AD
Corvus Pharmaceuticals (NASDAQ: CRVS) announced encouraging results from cohort 4 of its Phase 1 trial of soquelitinib in moderate to severe atopic dermatitis. The data show good safety and efficacy, similar to earlier cohorts, and suggest longer treatment may improve responses. Cohort 4 Results Cohort 4 included 12 patients on soquelitinib and 12 on placebo.…
